| 序号 | 专利名 | 申请号 | 申请日 | 公开（公告）号 | 公开（公告）日 | 发明人 |
|---|---|---|---|---|---|---|
| 1 | Combination Products For Treating Cancer | US12681943 | 2008-10-10 | US20100222418A1 | 2010-09-02 | Louis Buscail; Gerard Tiraby; Fabienne Vernejoul; Christiane Susini; Daniel Drocourt |
| The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | ||||||
| 2 | Antimicrobial methods and materials | US09966521 | 2001-09-28 | US20030087321A1 | 2003-05-08 | Che-Shen C. Tomich; Cheryl L. Quinn; Staffan Arvidson; John E. Mott; Douglas W. Harris |
| The present invention provides methods of identifying agents that bind gene products critical for the survival of microbes, preferably Staphylococcus microbes, including agents that interfere with the expression of such gene products and agents that interfere with the function of such gene products. | ||||||
| 3 | 癌治療用の組合せ製品 | JP2014248364 | 2014-12-08 | JP5933674B2 | 2016-06-15 | ルイ、ビュスカーイユ; ジェラール、ティラビ; ファビエンヌ、ベルヌジュール; クリスチアーヌ、スサニ; ダニエル、ドロクール |
| 4 | Combination product for the treatment of cancer | JP2010528416 | 2008-10-10 | JP2011500011A | 2011-01-06 | クリスチアーヌ、スサニ; ジェラール、ティラビ; ダニエル、ドロクール; ファビエンヌ、ベルヌジュール; ルイ、ビュスカーイユ |
| 本発明は、被験者の癌治療に用いられる同時、個別または逐次使用のための製剤としての、
(i) 配列番号1の配列を有するヒトソマトスタチン2受容体タンパク質(sst2)、その相同分子種または誘導体をコードする少なくとも1種類の核酸配列、 (ii) 配列番号2の配列を有するデオキシシチジンキナーゼタンパク質(dck)、その相同分子種または誘導体をコードする少なくとも1種類の核酸配列、 (iii) 配列番号3の配列を有するヒトウリジンモノホスフェートキナーゼタンパク質(umk)、その相同分子種または誘導体をコードする少なくとも1種類の核酸配列、および (iv) ゲムシタビンを含む製品に関する。 |
||||||
| 5 | Combination products for treating cancer | EP07301447.4 | 2007-10-10 | EP2047858A1 | 2009-04-15 | The designation of the inventor has not yet been filed |
The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO:1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO:3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. |
||||||
| 6 | COMBINATION PRODUCTS FOR TREATING CANCER | EP08844792.5 | 2008-10-10 | EP2209484A1 | 2010-07-28 | BUSCAIL, Louis; TIRABY, Gérard; VERNEJOUL, Fabienne; SUSINI, Christiane; DROCOURT, Daniel |
| The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | ||||||
| 7 | COMBINATION PRODUCTS FOR TREATING CANCER | EP08844792.5 | 2008-10-10 | EP2209484B1 | 2013-03-20 | BUSCAIL, Louis; TIRABY, Gérard; VERNEJOUL, Fabienne; SUSINI, Christiane; DROCOURT, Daniel |
| 8 | Somatostatin 2 receptor (sst2), deoxycytidine kinase (dck) and uridine monophosphate kinase (umk) pancreatic gene therapy | US12681943 | 2008-10-10 | US09364494B2 | 2016-06-14 | Louis Buscail; Gérard Tiraby; Fabienne Vernejoul; Christiane Susini; Daniel Drocourt |
| The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | ||||||
| 9 | COMBINATION PRODUCTS FOR TREATING CANCER | US14588585 | 2015-01-02 | US20150190480A1 | 2015-07-09 | LOUIS BUSCAIL; GERARD TIRABY; FABIENNE VERNEJOUL; CHRISTIANE SUSINI; DANIEL DROCOURT |
| The present invention concerns products containing (i) at least one nucleic acid sequence coding for the human somatostatin 2 receptor protein (sst2) having the sequence SEQ ID NO: 1, ortholog or derivative thereof, (ii) at least one nucleic acid sequence coding for the human deoxycytidine kinase protein (dck) having the sequence SEQ ID NO:2, ortholog or derivative thereof, (iii) at least one nucleic acid sequence coding for the human uridine monophosphate kinase protein (umk) having the sequence SEQ ID NO: 3 ortholog or derivative thereof, and (iv) gemcitabine, as a combined preparation for simultaneous, separate, or sequential use for treating cancer in a subject. | ||||||
| 10 | METHOD FOR QUANTIFYING 5-HYDROXYMETHYLCYTOSINE | US14210785 | 2014-03-14 | US20140272970A1 | 2014-09-18 | Hicham Zegzouti; Laurie Engel; Said A. Goueli |
| Provided herein are methods for detecting and quantifying 5-hydroxymethylated cytosine bases in a DNA molecule. | ||||||
| 11 | Antimicrobial methods and materials | US10429094 | 2003-05-02 | US20030180821A1 | 2003-09-25 | Che-Shen C. Tomich; Cheryl L. Quinn; Staffan Arvidson; John E. Mott; Douglas W. Harris |
| The present invention provides methods of identifying agents that bind gene products critical for the survival of microbes, preferably Staphylococcus microbes, including agents that interfere with the expression of such gene products and agents that interfere with the function of such gene products. | ||||||
| 12 | 癌治療用の組合せ製品 | JP2014248364 | 2014-12-08 | JP2015091826A | 2015-05-14 | ルイ、ビュスカーイユ; ジェラール、ティラビ; ファビエンヌ、ベルヌジュール; クリスチアーヌ、スサニ; ダニエル、ドロクール |
| 【課題】膵臓癌または肝細胞癌および転移癌のような癌の治療法の提供。 【解決手段】癌治療に用いられる、同時、個別または逐次使用のための組合せ製剤としての製品であって、(i)特定の配列を有するヒトソマトスタチン2受容体タンパク質(sst2)、その相同分子種または誘導体をコードする少なくとも1種類の核酸、(ii)特定の配列を有するヒトデオキシシチジンキナーゼタンパク質(dck)、その相同分子種または誘導体をコードする少なくとも1種類の核酸、(iii)特定の配列を有するヒトウリジンモノホスフェートキナーゼタンパク質(umk)、その相同分子種または誘導体をコードする少なくとも1種類の核酸、および(iv)ゲムシタビンを含む、製品。前記配列が少なくとも各々90%の同一性を有する配列をコードする各々の核酸を含む製品。 【選択図】なし |
||||||
| 13 | 癌治療用の組合せ製品 | JP2010528416 | 2008-10-10 | JP5710259B2 | 2015-04-30 | ルイ、ビュスカーイユ; ジェラール、ティラビ; ファビエンヌ、ベルヌジュール; クリスチアーヌ、スサニ; ダニエル、ドロクール |
QQ群二维码
意见反馈
意见反馈